Research Analysts Issue Forecasts for JSPR FY2026 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Jasper Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($3.96) per share for the year. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

JSPR has been the subject of a number of other reports. UBS Group decreased their price objective on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Finally, Oppenheimer reduced their price objective on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $62.22.

Jasper Therapeutics Stock Up 0.2%

Shares of JSPR traded up $0.01 during mid-day trading on Tuesday, hitting $5.58. 151,017 shares of the company's stock were exchanged, compared to its average volume of 301,702. The stock has a market cap of $83.82 million, a price-to-earnings ratio of -1.18 and a beta of 2.72. The firm has a fifty day moving average of $4.87 and a two-hundred day moving average of $8.68. Jasper Therapeutics has a twelve month low of $3.13 and a twelve month high of $26.05.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its holdings in shares of Jasper Therapeutics by 12.6% during the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock worth $316,000 after buying an additional 1,652 shares during the last quarter. Barclays PLC increased its position in Jasper Therapeutics by 13.6% during the fourth quarter. Barclays PLC now owns 18,334 shares of the company's stock worth $392,000 after acquiring an additional 2,188 shares during the period. Wellington Management Group LLP raised its stake in Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock valued at $579,000 after purchasing an additional 3,310 shares during the last quarter. Wells Fargo & Company MN raised its stake in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock valued at $159,000 after purchasing an additional 3,828 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in Jasper Therapeutics by 0.9% in the 4th quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company's stock valued at $9,901,000 after purchasing an additional 4,000 shares during the period. Institutional investors and hedge funds own 79.85% of the company's stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.